HEL · ORNBV.HE
Orion Oyj
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
Loading market information…
HEL · OPTOMED.HE · EUR
Stock price, earnings
Quote as of Oct 30, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Optomed Oyj’s quoted price sits in the lower half of its reported 52-week range, 67.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Optomed Oyj’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -€0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Optomed Oyj’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Optomed Oyj, established in 2004 and headquartered in Oulu, Finland, is a medical technology company specializing in the development, production, and sale of portable devices for retinal examination and advanced screening software. The company operates globally, with a presence in Finland and China, structured into dedicated Devices and Software segments. Its Device division focuses on fundus cameras, serving a broad spectrum of medical specialists, including ophthalmologists, pediatricians, endocrinologists, neurologists, and general practitioners. These camera products are marketed under Optomed's own brand names such as Optomed Smartscope Pro, Aurora, Polaris, and Halo, and are also provided as OEM products under labels including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal. The Software segment offers a comprehensive suite of solutions. For eye health, this includes Avenue Eye Screen for managing the workflow of eye disease screening and monitoring (like diabetic retinopathy), Avenue Archive for healthcare data storage and transmission, Avenue Telemedicine for remote image analysis, Avenue AI for automated diabetic retinopathy screening, and Avenue Sync for seamless integration of fundus cameras with hospital systems. Beyond eye care, Optomed provides Avenue Cancer Screen for managing breast, cervical, and colorectal cancer screenings; Optomed RIS for optimizing diagnostic processes in healthcare imaging units; Sectra PACS, a scalable system for high-volume healthcare providers; Optomed Service Portal for supporting imaging service operations; Facad for visible light imaging and cephalometric tracing; and Sectra PACS Pathology, a digital solution for the distribution and diagnosis of scanned glass slides. Furthermore, Optomed extends professional IT consulting services to government bodies. The company's products and solutions are distributed through OEMs, authorized distributors, and its direct sales channels. Its primary clientele includes hospitals, specialized eye clinics, and both independent and chain optician stores.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:51 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 6, 2025 |
| -€0.08+11.11% vs estimate |
| €4.02M-8.61% vs estimate |
| Q4 2024 | Feb 13, 2025 | -€0.05-25.0% vs estimate | €5.10M-0.01% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -€0.09-28.57% vs estimate | €3.11M-22.28% vs estimate |
|---|
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
€6.04+€0.03 (+0.5%)
Terveystalo Oyj’s quoted price sits in the lower half of its reported 52-week range, 42.03% below the high.
€10.38-€0.02 (-0.19%)
Revenio Group Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.15% below the high.
€8.80-€0.07 (-0.79%)
Nexstim Plc’s quoted price sits in the lower half of its reported 52-week range, 42.67% below the high.
€0.80+€0.15 (+22.48%)
Nanoform Finland Oyj’s quoted price sits in the lower half of its reported 52-week range, 34.98% below the high.
€1.01-€0.01 (-0.99%)
Modulight Oyj’s quoted price sits in the lower half of its reported 52-week range, 27.17% below the high.
€2.11-€0.04 (-1.86%)
Biohit Oyj’s quoted price sits in the lower half of its reported 52-week range, 44.18% below the high.
€1.18-€0.02 (-1.67%)
Herantis Pharma Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.89% below the high.
